• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肌肉活检在杜氏肌营养不良症临床试验中的应用——患者和照护者的观点。

Muscle biopsies in clinical trials for Duchenne muscular dystrophy - Patients' and caregivers' perspective.

机构信息

Duchenne Parent Project Netherlands, the Netherlands; Department of Human Genetics, Leiden University Medical Center, the Netherlands.

Duchenne UK, UK.

出版信息

Neuromuscul Disord. 2019 Aug;29(8):576-584. doi: 10.1016/j.nmd.2019.06.004. Epub 2019 Jun 12.

DOI:10.1016/j.nmd.2019.06.004
PMID:31378431
Abstract

The number of clinical trials for Duchenne muscular dystrophy is increasing. Many trials require muscle biopsies, which involve an invasive surgical procedure. Little is known about short- and long-term impacts of muscle biopsies as perceived by patients and caregivers. Therefore a survey was held among patients and their caregivers who participated in trials involving muscle biopsies, in seven countries. Seventy-eight responses were received. Analysis revealed that many patients and parents had significant anxiety before the biopsy. The main concern of caregivers was the required general anaesthesia. In most cases biopsies caused pain and temporarily hampered daily activities. The main long-term impact was scarring, although large variation in size was reported. Seventy-nine percent of caregivers were little bothered and 21% were moderately or severely bothered by the scar. Willingness to consider another biopsy in future protocols was higher for open-label studies than for placebo-controlled trials. Caregivers stressed the importance of knowing the results of biopsy analyses; only a minority actually received this information. Recommendations are made on the informed consent procedure regarding risks and consequences of muscle biopsies, and communication of results. Furthermore, efforts should be made to minimise the impact of biopsies through pain management and by considering plastic surgery.

摘要

杜氏肌营养不良症的临床试验数量正在增加。许多试验需要进行肌肉活检,这涉及到一种有创的外科手术。患者和护理人员对肌肉活检的短期和长期影响知之甚少。因此,在七个国家对参与涉及肌肉活检试验的患者及其护理人员进行了调查。共收到 78 份回复。分析表明,许多患者和家长在活检前有明显的焦虑。护理人员主要关注的是所需的全身麻醉。在大多数情况下,活检会引起疼痛,并暂时妨碍日常活动。主要的长期影响是疤痕,尽管报告的大小差异很大。79%的护理人员对此疤痕几乎没有困扰,21%的护理人员有中度或严重困扰。在未来的方案中,愿意考虑再次进行开放性研究而非安慰剂对照试验的活检意愿更高。护理人员强调了解活检分析结果的重要性;只有少数人实际上收到了这些信息。就肌肉活检的风险和后果的知情同意程序以及结果的沟通提出了建议。此外,应通过疼痛管理和考虑整形手术来努力减轻活检的影响。

相似文献

1
Muscle biopsies in clinical trials for Duchenne muscular dystrophy - Patients' and caregivers' perspective.肌肉活检在杜氏肌营养不良症临床试验中的应用——患者和照护者的观点。
Neuromuscul Disord. 2019 Aug;29(8):576-584. doi: 10.1016/j.nmd.2019.06.004. Epub 2019 Jun 12.
2
Anaesthetic management in patients with Duchenne muscular dystrophy undergoing orthopaedic surgery: a review of 232 cases.杜氏肌营养不良症患者行骨科手术的麻醉管理:232 例回顾性研究
Eur J Anaesthesiol. 2012 Oct;29(10):489-94. doi: 10.1097/EJA.0b013e3283566789.
3
Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best-worst scaling experiment in caregivers and adult patients.在决定参与杜氏肌营养不良症早期基因治疗试验时的优先事项:照顾者和成年患者的最佳-最差比例实验。
Orphanet J Rare Dis. 2019 May 9;14(1):102. doi: 10.1186/s13023-019-1069-6.
4
Dexmedetomidine and ketamine sedation for muscle biopsies in patients with Duchenne muscular dystrophy.右美托咪定和氯胺酮用于杜氏肌营养不良症患者肌肉活检的镇静作用。
Paediatr Anaesth. 2014 Aug;24(8):851-6. doi: 10.1111/pan.12387. Epub 2014 Mar 20.
5
Tamoxifen in Duchenne muscular dystrophy (TAMDMD): study protocol for a multicenter, randomized, placebo-controlled, double-blind phase 3 trial.他莫昔芬治疗杜氏肌营养不良症(TAMDMD):一项多中心、随机、安慰剂对照、双盲3期试验的研究方案
Trials. 2019 Nov 21;20(1):637. doi: 10.1186/s13063-019-3740-6.
6
[Analysis of 18 cases of Becker muscular dystrophy].[18例贝克型肌营养不良症分析]
Rev Neurol. 2004;38(11):1090-2.
7
A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.一种社区参与式方法,用于量化护理人员对杜氏肌营养不良症新兴疗法的益处和风险的偏好。
Clin Ther. 2014 May;36(5):624-37. doi: 10.1016/j.clinthera.2014.04.011.
8
Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study.通过L-精氨酸和二甲双胍改善杜氏肌营养不良症的肌肉功能:一项研究者发起的、开放标签、单中心、概念验证研究。
PLoS One. 2016 Jan 22;11(1):e0147634. doi: 10.1371/journal.pone.0147634. eCollection 2016.
9
Development and content validation of the Muscular Dystrophy Child Health Index of Life with Disabilities questionnaire for children with Duchenne muscular dystrophy.中文译文:《杜氏肌营养不良症儿童生活障碍残疾健康指数问卷》的编制及内容效度验证。
Dev Med Child Neurol. 2019 Jan;61(1):75-81. doi: 10.1111/dmcn.13977. Epub 2018 Jul 29.
10
Development of a Clinical Global Impression of Change (CGI-C) and a Caregiver Global Impression of Change (CaGI-C) measure for ambulant individuals with Duchenne muscular dystrophy.开发一种用于走动的杜氏肌营养不良症患者的临床总体印象变化量表(CGI-C)和照料者总体印象变化量表(CaGI-C)。
Health Qual Life Outcomes. 2021 Jul 26;19(1):184. doi: 10.1186/s12955-021-01813-w.

引用本文的文献

1
Contrasting Becker and Duchenne muscular dystrophy serum biomarker candidates by using data independent acquisition LC-MS/MS.通过数据非依赖采集液相色谱-串联质谱法对比贝克型和杜兴氏肌营养不良症的血清生物标志物候选物。
Skelet Muscle. 2025 Jun 7;15(1):15. doi: 10.1186/s13395-025-00385-3.
2
Label-free Detection of Urine Extracellular Vesicles from Duchenne Muscular Dystrophy Patients Using Surface-Enhanced Raman Spectroscopy Combined with Machine Learning Models.使用表面增强拉曼光谱结合机器学习模型对杜氏肌营养不良症患者尿液细胞外囊泡进行无标记检测。
ACS Omega. 2025 Mar 24;10(16):16874-16883. doi: 10.1021/acsomega.5c00838. eCollection 2025 Apr 29.
3
Dystrophinopathy patient data as a guide to interpretation of pregestational female population screening for DMD gene variants.
杜氏肌营养不良症患者数据可作为解读女性孕前人群杜氏肌营养不良症基因变异筛查结果的指导。
Neurogenetics. 2024 Nov 20;26(1):2. doi: 10.1007/s10048-024-00788-2.
4
Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease.行业指南草案:杜氏肌营养不良症、贝克肌营养不良症和相关肌营养不良症——为整个疾病谱开发潜在的治疗方法。
J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219.
5
Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation.面肩肱型肌营养不良症欧洲患者调查:评估患者报告的疾病负担及参与临床试验的偏好
J Neuromuscul Dis. 2024;11(2):459-472. doi: 10.3233/JND-230171.
6
Re-examination of therapeutic management of muscular dystrophies using a vascular smooth muscle-centered approach.采用以血管平滑肌为中心的方法重新审视肌营养不良症的治疗管理。
J Smooth Muscle Res. 2023;59:67-80. doi: 10.1540/jsmr.59.67.
7
The Dilemma of Choice for Duchenne Patients Eligible for Exon 51 Skipping The European Experience.适合外显子 51 跳跃的杜氏肌营养不良症患者的选择困境:欧洲经验。
J Neuromuscul Dis. 2023;10(3):315-325. doi: 10.3233/JND-221648.
8
Modeling Patient-Specific Muscular Dystrophy Phenotypes and Therapeutic Responses in Reprogrammed Myotubes Engineered on Micromolded Gelatin Hydrogels.在微模塑明胶水凝胶上工程化的重编程肌管中模拟特定患者的肌营养不良表型和治疗反应。
Front Cell Dev Biol. 2022 Apr 6;10:830415. doi: 10.3389/fcell.2022.830415. eCollection 2022.
9
Study of Clinical Features and Diagnosis Pattern of Duchene Muscular Dystrophy in Southern India.印度南部杜兴氏肌营养不良症的临床特征与诊断模式研究。
J Neurosci Rural Pract. 2022 Jan 5;13(1):43-49. doi: 10.1055/s-0041-1740614. eCollection 2022 Jan.
10
The Role of Patient Involvement When Developing Therapies.患者参与疗法开发的作用。
Nucleic Acid Ther. 2022 Apr;32(2):118-122. doi: 10.1089/nat.2021.0048. Epub 2021 Oct 1.